[Digital dermatoscopy for dysplastic nevi]
Mengarelli C, Ciapponi A, Alcaraz A, Pichon-Riviere A, Augustovski F, García Martí S, Bardach A
Record ID 32018001579
Spanish
Original Title:
Dermatoscopia digital para nevus displásico
Authors' recommendations:
There are no experimental studies which have assessed the clinical benefit of dermatoscopy on the survival or incidence of melanoma. For lesion excision, moderate-quality evidence suggests that adding manual or digital dermatoscopy to visual inspection of atypical melanocytic nevi and/or melanomas might significantly reduce the need for diagnostic excision. The use of digital dermatoscopy increases the likelihood of detecting lesions that should be resected.
The clinical practice guidelines suggest that dermatoscopy should be used for differential diagnosis of pigmented skin lesions and that digital dermatology should be used in patients at high risk of developing melanoma.
Different health funders from Europe, the United States and Latin America define the use of digital dermatoscopy as a means of diagnosis, and follow up of lesions such as dysplastic nevi to prevent the development of melanoma in total body scans, as an aid to determine resection borders of atypical nevi or lesions consistent with melanoma. They define that after lesion excision or in case close monitoring is required, this should be performed every three months.
Details
Project Status:
Completed
Year Published:
2020
URL for published report:
https://www.iecs.org.ar/home-ets/
English language abstract:
An English language summary is available
Publication Type:
Not Assigned
Country:
Argentina
MeSH Terms
- Skin Neoplasms
- Melanoma
- Dermoscopy
- Diagnostic Imaging
Contact
Organisation Name:
Institute for Clinical Effectiveness and Health Policy
Contact Address:
Dr. Emilio Ravignani 2024, Buenos Aires - Argentina, C1414 CABA
Contact Name:
info@iecs.org.ar
Contact Email:
info@iecs.org.ar
Copyright:
Institute for Clinical Effectiveness and Health Policy (IECS)
This is a bibliographic record of a published health technology assessment from a member of INAHTA or other HTA producer. No evaluation of the quality of this assessment has been made for the HTA database.